- More than 80 percent of MS specialists in the U.S. have prescribed AUBAGIO;
- Approximately 1 in 5 patients prescribed AUBAGIO were treatment-naïve;
- More than 50 percent of AUBAGIO patients were most recently on Copaxone ® or Avonex ®
Jim Cramer says next week's earnings calendar is littered with brick-and-mortar roadkill.
Growth is obvious everywhere; yes, even in Italy or Latin America.
Bank stocks led the charge across Europe after hawkish Janet Yellen comments.